Office Action Predictor
Last updated: April 16, 2026
Application No. 19/346,566

Devices, Systems, and Methods for an Implantable Heart-Valve Adapter

Non-Final OA §102§103
Filed
Oct 01, 2025
Examiner
GANESAN, SUBA
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Revalve Solutions, INC.
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
3y 4m
To Grant
88%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
491 granted / 667 resolved
+3.6% vs TC avg
Moderate +14% lift
Without
With
+14.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
30 currently pending
Career history
697
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
45.5%
+5.5% vs TC avg
§102
26.6%
-13.4% vs TC avg
§112
19.3%
-20.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 667 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 5-6 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Figulla et al. (Pub. No.: US 2014/0088696). Figulla et al. (hereinafter Figulla) discloses an implantable heart-valve apparatus (e.g., fig. 1), comprising: a tubular braided (e.g., para. 19) frame, wherein the tubular braided frame comprises an inflow end (end with atrial side anchoring elements 6a-d) and an outflow end (end with ventricular-side anchoring members 4a-d); wherein the tubular braided frame extends out from the inflow end to form at least one flange (fig. 1); and wherein the tubular braided frame extends out from the outflow end to form engagement attachments 4a-d comprising a leaflet anchor 4b, 4c (e.g., fig. 2) and two shape set stabilization anchors 4a, 4d (e.g., fig. 2), wherein the engagement attachments are integrated with the tubular braided frame to define a single component (fig. 1), wherein the leaflet anchor is disposed between the two shape set stabilization anchors (fig. 1, 2). For claim 5, Figulla discloses the apparatus of claim 1, wherein the two shape set stabilization anchors are between 120 to 180 degrees apart (e.g., fig. 1, 2). For claim 6, Figulla discloses the apparatus of claim 1, wherein the tubular braided frame contains a replacement heart valve (e.g., para. 23). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 7, 11-12, 15, 17-18 are rejected under 35 U.S.C. 103 as being unpatentable over Figulla et al. (Pub. No.: US 2014/0088696) in view of Chang et al. (Pub. No.: US 2017/0156859). For claim 7, Figulla discloses an implantable heart valve system, comprising: an implantable heart-valve apparatus (e.g., fig. 1) comprising a tubular braided (e.g., para. 19) frame, having an inflow end (end with atrial side anchoring elements 6a-d) and an outflow end (end with ventricular-side anchoring members 4a-d); a flange extending from the inflow end of the tubular braided frame (fig. 1); and a plurality of engagement attachments 4a-d extending out from the outflow end, the engagement attachments comprising a leaflet anchor 4b. 4c (e.g., fig. 2) and two shape set stabilization anchors 4a, 4d (e.g., fig. 2), wherein the leaflet anchor is disposed between the two shape set stabilization anchors (e.g., fig. 1), wherein the tubular braided frame and the plurality of engagement attachments define a singular component (e.g., fig. 1); a delivery component comprising one or more suture lines connected on a first end to the implantable heart-valve apparatus; wherein the one or more suture lines connects on a second end to the delivery component (not disclosed). As provided in italicized text above, Figulla lacks a delivery component with one ore more suture lines connected on a first end to the implantable heart valve apparatus and on a second end to the delivery component. Figulla does include rings 4’ and 6’ on the end of each anchoring element, however, Figulla does not suggest that these rings are used for a suture line interconnected with a delivery component. Chang et al. (hereinafter, Change) teaches interconnecting a delivery catheter with a heart valve implant using suture loops 172 interconnected with a delivery catheter 104 for the purpose of providing control over the expansion and compression of the prosthetic valve (e.g., para. 79). It would have been obvious to one of ordinary skill in the art at the time the invention was filed to have provided the Figulla implant with suture loops and a delivery catheter as taught by Chang for the purpose of providing reversible control over the deployment of the prosthetic valve, ensuring more accurate placement. This modification would have occurred using known methods and would have yielded predictable results. For claim 11, Figulla discloses the system of claim 7, wherein the two shape set stabilization anchors are between 120 to 180 degrees apart (e.g., fig. 1, 2). For claim 12, Figulla discloses a method for percutaneous deployment and placement (e.g., para. 5) of an implantable heart-valve apparatus, comprising: an implantable heart-valve apparatus 2 and a delivery component (e.g., para. 5); wherein the implantable heart-valve apparatus comprises a tubular braided frame (e.g., para. 19), an inflow end (end with atrial side anchoring elements 6a-d) and an outflow end (end with ventricular-side anchoring members 4a-d); wherein the tubular braided frame extends out from the inflow end to form at least one flange (fig. 1); and wherein the tubular braided frame extends out from the outflow end to form engagement attachments 4a-d comprising a leaflet anchor4b, 4c and two shape set stabilization anchors 4a, 4d (e.g., fig. 2), wherein the leaflet anchor is disposed between the two shape set stabilization anchors (e.g., fig. 1), wherein the tubular braided frame and at least one of the two shape set stabilization anchors are integrally formed as a single component (e.g., para. 17); wherein the delivery component comprises one or more suture lines and wherein the one or more suture lines goes through the heart-valve apparatus and connects to the delivery component (not disclosed); percutaneously placing the implantable heart-valve apparatus into one of a vein or an artery (e.g., para. 26); delivering the implantable heart-valve apparatus to a native heart valve; placing the implantable heart-valve apparatus in the position of the native heart valve (e.g., para. 26); and expanding the engagement attachments by releasing one or more of the suture lines (not disclosed), wherein when deployed in a native valve comprising a native annulus and one or more native leaflets, the leaflet anchor engages behind the one or more native leaflets and the two shape set stabilization anchors extend towards the native annulus (e.g., fig. 2). As provided in italicized text above, Figulla lacks a delivery component with one ore more suture lines connected on a first end to the implantable heart valve apparatus and on a second end to the delivery component, and the method step of expanding the engagement attachments by releasing one or more of the suture lines. Figulla does include rings 4’ and 6’ on the end of each anchoring element, however, Figulla does not suggest that these rings are used for a suture line interconnected with a delivery component. Chang et al. (hereinafter, Change) teaches interconnecting a delivery catheter with a heart valve implant using suture loops 172 interconnected with a delivery catheter 104 for the purpose of providing control over the expansion and compression of the prosthetic valve (e.g., para. 79). These suture loops engage openings on the heart valve prosthesis and allow for expansion by releasing the suture lines (e.g., para. 79). It would have been obvious to one of ordinary skill in the art at the time the invention was filed to have provided the Figulla implant with suture loops and a delivery catheter as taught by Chang for the purpose of providing reversible control over the deployment of the prosthetic valve, ensuring more accurate placement. It would have been obvious to one of ordinary skill in the art to have provided the suture line son the engagement attachments as an obvious location to control the expansion and contraction of the engagement attachments during implant delivery. This modification would have occurred using known methods and would have yielded predictable results. For claim 15, Figulla discloses the method of claim 12, wherein the vein is a femoral vein and wherein delivering the implantable heart-valve apparatus to a native heart valve comprises delivering the implantable heart-valve apparatus through the vena cava and through a puncture in the atrial septum (e.g., para. 27). Use of the femoral vein to access the trans-septal implant procedure is considered an obvious expedient. For claim 17, Figulla discloses the method of claim 12, wherein the two shape set stabilization anchors are between 120 to 180 degrees apart (fig. 1). For claim 18, Figulla discloses the method of claim 12, wherein the tubular braided frame is a receiver for a replacement heart valve (abstract). Claims 2-4 are rejected under 35 U.S.C. 103 as being unpatentable over Figulla et al. (Pub. No.: US 2014/0088696) in view of Haug et al. (Pub. No.: US 2005/0137693). For claims 2-4, Figulla does not specify the engagement attachments are grafted on the tubular braided frame, are welded onto the frame, or comprise a tubular braided frame first wire and an engagement attachment second wire attached to the first wire. Figulla does teach the engagement attachments are integral to the tubular braided frame (para. 17), and welding is a known means of providing an integral attachment. Additionally, Haug et al. (hereinafter, Haug) teaches welded ends on a braided prosthesis as a suitable attachment (e.g., fig. 7A-J). Haug further teaches braiding two wires, where the tubular body is a first wire and an engagement attachment is a second wire (e.g., fig. 10C). This is considered a grafted engagement attachment. It would have been obvious to one of ordinary skill in the art at the time the invention was filed to have provided Figulla with multiple wire braids, grafted engagement attachments, and welds as taught by Haug as an obvious expedient to provide the integral braided structure of Figulla. This modification would have occurred using known methods and would have yielded predictable results. Claims 8-10, 13-14, 16 are rejected under 35 U.S.C. 103 as being unpatentable over Figulla et al. (Pub. No.: US 2014/0088696) in view of Chang et al. (Pub. No.: US 2017/0156859), further in view of Haug et al. (Pub. No.: US 2005/0137693). For claims 8-10, 13-14, 16, Figulla and Chen do not specify the engagement attachments are grafted on the tubular braided frame, are welded onto the frame, or comprise a tubular braided frame first wire and an engagement attachment second wire attached to the first wire. Figulla does teach the engagement attachments are integral to the tubular braided frame (para. 17), and welding is a known means of providing an integral attachment. Additionally, Haug teaches welded ends on a braided prosthesis as a suitable attachment (e.g., fig. 7A-J). Haug further teaches braiding two wires, where the tubular body is a first wire and an engagement attachment is a second wire (e.g., fig. 10C). This is considered a grafted engagement attachment. It would have been obvious to one of ordinary skill in the art at the time the invention was filed to have provided Figulla and Chen with multiple wire braids, grafted engagement attachments, and welds as taught by Haug as an obvious expedient to provide the integral braided structure of Figulla. This modification would have occurred using known methods and would have yielded predictable results. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUBA GANESAN whose telephone number is (571)272-3243. The examiner can normally be reached Monday-Friday, 8 AM - 5 PM Mountain Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jerrah Edwards can be reached at (408) 918-7557. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUBA GANESAN/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Oct 01, 2025
Application Filed
Dec 07, 2025
Response after Non-Final Action
Feb 04, 2026
Non-Final Rejection — §102, §103
Mar 30, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594160
PROSTHETIC HEART VALVE
2y 5m to grant Granted Apr 07, 2026
Patent 12588988
IMPLANT DELIVERY
2y 5m to grant Granted Mar 31, 2026
Patent 12588989
IMPLANT DELIVERY
2y 5m to grant Granted Mar 31, 2026
Patent 12582520
IMPLANT DELIVERY
2y 5m to grant Granted Mar 24, 2026
Patent 12575928
Devices, Systems, and Methods for an Implantable Heart-Valve Adapter
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
88%
With Interview (+14.0%)
3y 4m
Median Time to Grant
Low
PTA Risk
Based on 667 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month